Following strengthening rumors in recent weeks, Takeda Pharmaceutical Co. Ltd. has confirmed it has finalized an agreement to shed a selected portfolio of over-the-counter (OTC) and prescription pharmaceuticals in multiple markets in the Near/Middle East and Africa to Swiss firm Acino Holding AG, for a total value of around $200m.
The proceeds from the divestment will go some way towards further deleveraging the mountain of debt taken on to fund the acquisition of Shire PLC, while honing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?